PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Häfner, F. ; Johansson, C.* ; Schwarzkopf, L. ; Forster, K.* ; Kraus, Y.* ; Flemmer, A.W.* ; Hansmann, G.* ; Sallmon, H.* ; Felderhoff-Müser, U.* ; Witt, S. ; Schwettmann, L. ; Hilgendorff, A.

Current diagnosis and treatment practice for pulmonary hypertension in bronchopulmonary dysplasia-A survey study in Germany (PUsH BPD).

Pulm. Circ. 13:e12320 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Pulmonary hypertension (PH) is the most severe complication in preterm infants with bronchopulmonary dysplasia (BPD) and associated with significant mortality. Diagnostic and treatment strategies, however, still lack standardization. By the use of a survey study (PH in BPD), we assessed clinical practice (diagnosis, treatment, follow-up) in preterm infants with early postnatal persistent pulmonary hypertension of the newborn (PPHN) as well as at risk for or with established BPD-associated PH between 06/2018 and 10/2020 in two-thirds of all German perinatal centers with >70 very low birthweight infants/year including their cardiology departments and outpatient units. Data were analyzed descriptively by measures of locations and distributional shares. In routine postnatal care, clinical presentation and echocardiography were reported as the main diagnostic modalities to screen for PPHN in preterm infants, whereas biomarkers brain natriuretic peptide/N-terminal pro b-type natriuretic peptide were infrequently used. For PPHN treatment, inhaled nitric oxide was used in varying frequency. The majority of participants agreed to prescribe diuretics and steroids (systemic/inhaled) for infants at risk for or with established BPD-associated PH and strongly agreed on recommending respiratory syncytial virus immunization and the use of home monitoring upon discharge. Reported oxygen saturation targets, however, varied in these patients in in- and outpatient care. The survey reveals shared practices in diagnostic and therapeutic strategies for preterms with PPHN and BPD-associated PH in Germany. Future studies are needed to agree on detailed echo parameters and biomarkers to diagnose and monitor disease next to a much-needed agreement on the use of pulmonary vasodilators, steroids, and diuretics as well as target oxygen saturation levels.
Impact Factor
Scopus SNIP
Altmetric
2.600
0.912
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Bronchopulmonary Dysplasia ; Chronic Lung Disease ; Clinical Practice ; Preterm Infant ; Pulmonary Hypertension; Inhaled Nitric-oxide; Chronic Lung-disease; Preterm Infants; Vascular-disease; Artery Hypertension; Management; Children; Risk; Echocardiography; Surfactant
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2045-8932
e-ISSN 2045-8940
Zeitschrift Pulmonary Circulation
Quellenangaben Band: 13, Heft: 4, Seiten: , Artikelnummer: e12320 Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
Institute of Health Economics and Health Care Management (IGM)
POF Topic(s) 30202 - Environmental Health
80000 - German Center for Lung Research
Forschungsfeld(er) Lung Research
Genetics and Epidemiology
PSP-Element(e) G-552100-001
G-505300-001
G-501800-533
Förderungen Research Training Group 'Targets in Toxicology' of the German Science and Research Organisation (DFG)
German Centre for Lung Research (DZL) (BMBF))
International Research Group'Role of BMP signaling', Helmholtz Foundation (Federal Ministry of Education and Research in Germany(BMBF))
Helmholtz Zentrum Muenchen, Germany
Helmholtz Foundation
Young Investigator "Molecular Mechanisms of Neonatal Chronic Lung Disease" by the Helmholtz Foundation and the Helmholtz Zentrum Muenchen, Germany
DOI 10.1002/pul2.12320
WOS ID 001138390700001
WOS ID 001138646600003
Scopus ID 85180434359
PubMed ID 38144949
Erfassungsdatum 2024-01-09
[➜Korrektur melden]